The Diversity-First Scoring Dimension represents a methodological approach to clinical trial site selection that explicitly prioritizes diversity considerations as a primary evaluation criterion rather than treating them as secondary constraints. This framework integrates regulatory compliance with the FDA's Diversity Action Plan, established under the FDA Omnibus Reform Act (FDORA) 2022, while employing machine learning interpretability techniques to ensure equitable institutional representation in clinical research ¹⁾.

The FDA's Diversity Action Plan, mandated by FDORA 2022, requires sponsors and clinical research organizations to systematically evaluate and improve diversity in clinical trial participation and site selection. Traditional site selection models often inadvertently deprioritize community-based and minority-serving institutions due to weighted scoring systems that emphasize enrollment speed, infrastructure complexity, or historical trial participation metrics. The Diversity-First Scoring Dimension addresses this structural bias by elevating diversity metrics—including representation of underserved populations, community-based sites, and institutions with established relationships to minority communities—to first-class status within the site selection algorithm ²⁾.

This approach reflects broader regulatory expectations that diversity in clinical research improves generalizability of findings across demographic populations and addresses historical inequities in medical research participation.

The framework leverages SHAP (SHapley Additive exPlanations) attribution methods to audit and validate site selection recommendations for systematic under-weighting of community and minority-serving institutions. SHAP values provide model-agnostic explanations of feature contributions to individual predictions, enabling stakeholders to identify when scoring algorithms systematically reduce recommendation weights for institutions serving specific demographic populations ³⁾.

The implementation process involves:

1. Baseline Model Assessment: Analyzing existing site selection scoring models to quantify the relative contribution of diversity-related features versus performance metrics 2. Feature Attribution Analysis: Using SHAP values to decompose recommendation scores for each prospective site, isolating how diversity characteristics influence final rankings 3. Bias Detection: Comparing SHAP attributions across site categories (community-based vs. academic, minority-serving vs. majority-serving) to identify systematic disparities in how the model weights institutional characteristics 4. Reweighting and Validation: Adjusting model parameters to ensure diversity dimensions receive appropriate weight, then validating through subsequent audits

This interpretability-driven approach ensures that diversity considerations influence site selection through transparent, auditable mechanisms rather than external post-hoc adjustments ⁴⁾.

In clinical operations, the Diversity-First Scoring Dimension reorganizes traditional site selection criteria into a hierarchy where diversity metrics receive weighted consideration alongside conventional factors such as:

- Enrollment capacity and historical recruitment performance - Protocol compliance capabilities and regulatory infrastructure - Patient population alignment with trial inclusion/exclusion criteria - Geographic distribution and access to target demographics

By implementing diversity as a first-class dimension, organizations explicitly balance the clinical and commercial efficiency objectives of rapid enrollment with the regulatory and scientific objectives of representative participant populations. This may result in selecting sites with slightly lower historical enrollment volumes but stronger community engagement or established recruitment relationships with underrepresented populations ⁵⁾.

Several technical and operational challenges accompany this approach. First, defining appropriate quantitative metrics for “diversity” remains methodologically complex, requiring alignment between regulatory expectations, clinical design objectives, and community-based definitions of meaningful inclusion. Second, SHAP-based auditing requires substantial computational resources and expertise in machine learning interpretability, potentially limiting adoption to larger organizations with specialized analytics capabilities.

Additionally, the Diversity-First approach may introduce trade-offs between enrollment velocity and diversity representation, requiring explicit discussion with trial sponsors regarding acceptable timelines and cost implications. Historical data limitations for minority-serving institutions may result in uncertainty regarding enrollment projections, necessitating adaptive planning frameworks rather than fixed site portfolios ⁶⁾.

Implementation of Diversity-First Scoring Dimensions increasingly occurs within data lakehouse environments that centralize diverse data sources—including site performance histories, community demographic data, institutional mission statements, and regulatory compliance records. This infrastructure enables rapid iteration of diversity metrics, continuous SHAP-based auditing, and integration with other clinical operations intelligence systems for end-to-end trial site optimization ⁷⁾.

• ML-Driven Site Scoring
• Site Feasibility Workbench vs Commercial Scoring Products
• Site Feasibility Workbench